Background
In recent years, the therapeutic effect of monoclonal antibody against programmed cell death protein-1 (PD-1) monotherapy or combined chemotherapy in patients with locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer has been confirmed by many studies. A number of clinical studies of anti-PD-1 antibody combined with chemotherapy in the perioperative treatment of locally advanced and resectable G/GEJ cancer are underway. The exploration and discovery of new biomarker combinations based on tumor characteristics and tumor microenvironment, especially tumor immune microenvironment, are helpful to screen superior patients and realize precise immunotherapy.
Methods
We selected 268 consecutive AGC patients who were treated with ICI therapy from December 2014 to May 2021. We measured their pretreatment the prognostic nutritional index (PNI) levels and performed univariate and multivariate Cox regression analyses of progression-free survival (PFS) or overall survival (OS) after ICI therapy.
Results
The low pretreatment PNI level of AGC patients was significantly correlated with shorter PFS (P<0.001) and OS (P<0.001) after ICI treatment. In univariate and multivariate analyses of the associations between neutrophil lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR) or PNI, and OS or PFS, PNI (HR=1.483; 95% CI, 1.129-1.947; P=0.005) and NLR (HR=1.531; 95% CI, 1.164-2.014; P=0.002), but not LMR (HR=1.130; 95% CI, 0.829-1.538;P=0.440) are independent prognostic factors for PFS. Moreover, PNI (HR=1.385; 95% CI, 1.004-1.911; P=0.048) and LMR (HR=1.433; 95% CI, 1.039-1.977; P=0.028), but not NLR (HR=1.277; 95% CI, 0.896-1.820; P=0.176) are independent prognostic factors for OS.
Conclusion
The pretreatment PNI might help to identify AGC patients who will obtain a survival benefit from ICI therapy. The low pretreatment PNI is related to unsatisfactory survival outcomes.